Independent · Sourced · Dated
Real Peptide Info with research sources
Evidence-graded profiles for every major peptide, plain-language summaries of the trials behind them, and the only continuously maintained map of peptide legality across all 50 US states and 26+ countries.
- 12
- Peptide profiles
- 14
- Studies summarized
- 77
- Jurisdictions tracked
- Weekly
- Update cadence
New here?
How can peptides help me?
Start from the problem instead of the compound. Each guide names the peptides studied for that goal and states plainly how strong the human evidence is.
Peptide Library
Mechanism, half-life, studied doses, evidence grade, and risks per compound.
OpenResearch Database
Trial-by-trial summaries with design, findings, and honest limitations.
OpenLaws & Legality
Status, telehealth access, and compounding rules by state and country.
OpenNews & Analysis
Weekly regulatory and research developments, with context.
OpenMost researched
Featured peptide profiles
Semaglutide
FDA-approvedMetabolic
A long-acting GLP-1 receptor agonist and the most rigorously studied weight-management peptide in modern medicine, with cardiovascular outcome data from tens of thousands of patients.
Tirzepatide
FDA-approvedMetabolic
A dual GIP/GLP-1 receptor agonist that produced the largest weight reductions ever recorded for a non-surgical intervention in randomized trials.
BPC-157
PreclinicalRepair & Recovery
A synthetic pentadecapeptide derived from human gastric juice protein BPC, with an extensive rodent literature on tendon, ligament, gut, and nerve healing — and almost no controlled human data.
TB-500 (Thymosin Beta-4 Fragment)
Phase IIRepair & Recovery
A synthetic fragment of the actin-sequestering protein thymosin beta-4, studied in cardiac repair and corneal/dermal wound healing, and heavily used off-label in veterinary and grey-market human settings.
CJC-1295 + Ipamorelin
Phase IGrowth Hormone
The most common growth-hormone secretagogue pairing: a GHRH analogue combined with a selective ghrelin-receptor agonist, intended to raise endogenous GH pulses rather than inject exogenous GH.
Tesamorelin
FDA-approvedGrowth Hormone
The only FDA-approved GHRH analogue, indicated for HIV-associated lipodystrophy, and one of the few peptides with randomized evidence for visceral-fat reduction and liver-fat improvement.
Strongest evidence
Trials worth knowing
- RCT · 2021
Once-Weekly Semaglutide 2.4 mg in Adults with Overweight or Obesity
New England Journal of Medicine
- RCT · 2023
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)
New England Journal of Medicine
- RCT · 2022
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
New England Journal of Medicine
- Phase II · 2023
Triple–Hormone-Receptor Agonist Retatrutide for Obesity
New England Journal of Medicine
This week
Latest developments
- Regulatory · 2026-08-10
What the FDA's 503A Category 2 List Actually Means for Peptide Access
The single most consequential regulatory action in the peptide space was not a ban — it was a bulk-substance classification that quietly removed BPC-157, CJC-1295, ipamorelin, and thymosin alpha-1 from lawful US compounding.
- Research · 2026-07-28
Retatrutide Phase III Data Sets a New Ceiling for Weight-Loss Pharmacology
The triple GIP/GLP-1/glucagon agonist has carried a ~24% Phase II weight-loss figure into Phase III, and the mechanistic addition of glucagon agonism is what makes the result interesting rather than merely larger.
- Safety · 2026-07-15
Independent Testing Keeps Finding the Same Problem in Grey-Market Peptide Vials
Mass-spectrometry analyses of consumer-purchased research peptides continue to report under-dosing, incorrect sequences, and endotoxin contamination in a meaningful fraction of samples.
Why this site exists
Peptide information online is split between hype and silence
Vendor blogs overstate preclinical rodent data as if it were clinical proof. Medical sources often decline to engage at all. Neither helps someone trying to understand what is actually known.
Every profile here carries an explicit evidence grade, the doses used in published studies, the risks reported in those studies, and the regulatory status that governs access — with a review date so you know how current it is.
When the evidence is thin, we say so. Preclinical means preclinical. That is the whole editorial position, and it is why researchers and clinicians cite these pages.